Hemispherx Biopharma (HEB) 0.22 $HEB
Hemispherx Biopharma FY14 results
Seeking Alpha - at Seeking Alpha - Fri Mar 20, 8:52AM CDT
HEB: 0.22 (-0.01)
Hemispherx Biopharma reports FY2014 results
Seeking Alpha - at Seeking Alpha - Fri Mar 20, 8:37AM CDT
HEB: 0.22 (-0.01)
Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2014
GlobeNewswire - Fri Mar 20, 8:28AM CDT
Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the year ended December 31, 2014. The net loss (including non-cash effects) was approximately $17,450,000 or $(0.09) per share as compared to a net loss of $16,225,000 or ($0.10) per share for the same twelve month period in 2013. Cash, cash equivalents and marketable securities were approximately $16,108,000 at December 31, 2014 as compared to $18,194,000 as of December 31, 2013.
HEB: 0.22 (-0.01)
Hemispherx Uses Ebola Tragedy to Raise Cash, Pay Executive Bonuses
at The Street - Tue Mar 10, 10:10AM CDT
Since the end of September, Hemispherx sold almost 25 million shares of company stock, equivalent to the amount of stock sold in the first nine months of 2014.
VRTX: 131.00 (-3.25), SGEN: 38.86 (-0.83), HEB: 0.22 (-0.01)
Hemispherx Enters a Collaboration with Emerge Health for the Commercialization of Ampligen for Chronic Fatigue Syndrome (CFS) in Australia and New Zealand
GlobeNewswire - Mon Mar 09, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
, reported today that it has executed an agreement with Emerge Health Pty Ltd. ("Emerge" to seek approval of Ampligen, an experimental immunotherapeutic, for Chronic Fatigue Syndrome in Australia and New Zealand and to commence distribution of Ampligen in both countries on a named-patient basis, where deemed appropriate.
HEB: 0.22 (-0.01)
Regulators Want Drug Companies to Be Honest About FDA
at The Street - Wed Mar 04, 12:08PM CST
The Securities and Exchange Commission's top cop wants drug companies to be more transparent with investors about their dealings with the U.S. Food and Drug Administration.
HEB: 0.22 (-0.01), AVEO: 1.35 (-0.16), AMPE: 8.52 (+0.08), SNY: 50.64 (+1.17)
Hemispherx Biopharma Announces the Completion of the Newly Upgraded Alferon(R) Facility: Commercial Production of Alferon(R) is in the Final Stage Integrating Continuous Flow Manufacturing Technology
GlobeNewswire - Mon Mar 02, 7:30AM CST
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" announced today that its manufacturing site located in New Brunswick, New Jersey, presently configured at over 43,000 square feet, has completed its $8 million of upgrades. These upgrades will provide for a higher capacity, more cost effective manufacturing process for the production of Alferon N Injection(R), the only FDA-approved natural alpha interferon. The added efficiency of the process has been accomplished by integrating continuous flow manufacturing technology throughout the process. This has led to improved cost efficiency, enhanced yields, real-time process monitoring, flexibility to tailor batch size for lean manufacturing, and improved operational safety as seen in other cutting edge pharmaceutical companies.
HEB: 0.22 (-0.01)
Biotech Weekly: 5 Factors Contributing To The Crazy Week That Was In Small Cap Biotech
Daniel Ward - at Seeking Alpha - Mon Feb 23, 7:40AM CST
HEB: 0.22 (-0.01), XBI: 233.86 (-4.12), IBIO: 0.79 (+0.02), IBB: 366.52 (+1.27), SPPI: 6.17 (-0.24), CLTX: 0.85 (+0.02)
WHO approves rapid test for Ebola
Seeking Alpha - at Seeking Alpha - Fri Feb 20, 6:15AM CST
BCRX: 9.49 (-0.74), TKMR: 19.48 (-1.01), GSK: 48.81 (+0.60), INO: 9.09 (-0.36), JNJ: 102.40 (+0.71), CMRX: 40.61 (-1.50), NVAX: 9.58 (-0.13), HEB: 0.22 (-0.01), MRK: 58.58 (+0.37), SRPT: 13.16 (-0.76), NLNK: 54.57 (-1.36), ABIO: 0.82 (-0.01), IBIO: 0.79 (+0.02)
What's New in the Biotechnology Sector: Special Research on Vical,Asterias, Bacterin, Hemispherx BioPharma, and IGI Laboratories
PR Newswire - Thu Feb 19, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
VICL: 0.97 (+0.01), BONE: 4.20 (-0.04), HEB: 0.22 (-0.01), AST: 7.88 (-0.40), IG: 9.32 (+0.65)
Hemispherx Biopharma and USAMRIID to Present New Discoveries Concerning the Efficacy of Ampligen(R) Against the Ebola Virus at Upcoming International Symposium on Filoviruses
GlobeNewswire - Thu Feb 12, 7:30AM CST
Ampligen(R) May Be an Important Candidate for EBOV Testing in West Africa
HEB: 0.22 (-0.01)
U.S. to pull troops from Ebola zone
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:38AM CST
INO: 9.09 (-0.36), JNJ: 102.40 (+0.71), BCRX: 9.49 (-0.74), HEB: 0.22 (-0.01), NLNK: 54.57 (-1.36), TKMR: 19.48 (-1.01), NNVC: 2.58 (-0.14), GSK: 48.81 (+0.60)
Hemispherx Biopharma Posts USAMRIID Ebola Study Concluding Ampligen(R) Produced 100% Survival Rate in Rodents With 100% Mortality in Placebo
GlobeNewswire - Mon Feb 09, 7:30AM CST
Based upon numerous Hemispherx stockholder requests, Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" has posted the report and findings of the recent efficacy study of Ampligen(R) in a mouse model of Ebola virus infection performed by scientists at the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID). The posted USAMRIID report conclusively refutes false and defamatory blog and online statements by TheStreet.com's blogger Adam Feuerstein and invalidates Feuerstein's negative social media postings about the company's press release that was issued on February 2, 2015.
HEB: 0.22 (-0.01)
Biotech Stock Mailbag: Hep C stocks, Bluebird, Advaxis, Hemispherx
at The Street - Fri Feb 06, 5:05AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
BLUE: 124.76 (-1.64), ADXS: 12.54 (+0.14), GILD: 102.29 (+0.85), HEB: 0.22 (-0.01), ACHN: 11.06 (-0.36), MRK: 58.58 (+0.37), ABBV: 60.40 (-0.79)
U.S. Army Medical Researchers to Hemispherx: We're Really Not That Into You
at The Street - Wed Feb 04, 11:59AM CST
A spokeswoman for the U.S. Army Medical Research Institute says its testing of Alferon and Ampligen drugs for ebola is complete and the relationship has ended.
HEB: 0.22 (-0.01)
Hemispherx: U.S. Army Scientists (USAMRIID) Find Ampligen(R) Produces 100% Survival Rate in Ebola Virus Rodent Study
GlobeNewswire - Mon Feb 02, 9:05AM CST
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" , announced today the results of a new efficacy study of Ampligen(R) in a mouse model of Ebola virus (EBOV) infection performed by scientists at the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID).
HEB: 0.22 (-0.01)
USAMRIID Reports Genetic Changes in Ebola Virus May Impede Potential Treatments
GlobeNewswire - Mon Jan 26, 7:30AM CST
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" , announced today that in a new publication in the journal mBio, scientists at the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID), Harvard University, and Massachusetts Institute of Technology (MIT) studied genetic changes in the Ebola virus (EBOV) circulating in West Africa and concluded that genomic drift of the EBOV over time may be sufficient to block the action of otherwise potential therapies that target EBOV genetic sequences. The types of potential drugs at risk include monoclonal antibodies and small-interfering RNA (siRNA) which are scheduled to be evaluated during the current outbreak (see below). The USAMRIID press release states that "genetic drift must be considered when developing potential therapeutics, in order to ensure that changes in the Ebola virus over time do not render those treatments ineffective......the USAMRIID team compared the current strain, called EBOV/Mak, with the two previous strains that caused outbreaks in 1976 and 1995 in Zaire (now the Democratic Republic of the Congo). In each comparison, they found more than 600 genetic mutations. Next, the group focused on only the mutations that occurred in the genetic sequences targeted by the experimental therapeutics. Of these, they found 10 new mutations that might interfere with the mechanisms of the sequence-based drugs currently being tested. Three of these mutations appeared during the current West African outbreak." (http://www.usamriid.army.mil/newsroom.htm).
HEB: 0.22 (-0.01)
NanoViricides up on report of Ebola drug progress
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 11:12AM CST
INO: 9.09 (-0.36), BCRX: 9.49 (-0.74), CMRX: 40.61 (-1.50), HEB: 0.22 (-0.01), SRPT: 13.16 (-0.76), ABIO: 0.82 (-0.01), TKMR: 19.48 (-1.01), NNVC: 2.58 (-0.14)
Hemispherx Biopharma Awarded $770,852 by Federal Judge
GlobeNewswire - Thu Jan 15, 7:59AM CST
Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx" announced that after prevailing in a federal lawsuit brought against the Company by Cato Capital, the United States District Court for the District of Delaware has ordered Cato to pay Hemispherx attorney's fees and costs in the amount of $770,852.76. Previously, in September 2014, the Court dismissed all claims brought by Cato against Hemispherx, including counts of breach of contract and fraudulent inducement--completely vindicating the Company of any wrongdoing.
HEB: 0.22 (-0.01)
Low Natural Killer (NK) Activity Observed Across the Chronic Fatigue Syndrome (CFS) Disease Spectrum
GlobeNewswire - Mon Jan 12, 8:16AM CST
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" , reported today that it has conducted new in vitro studies of natural killer (NK) cells obtained from CFS patients in conjunction with a comprehensive review of the medical literature to determine the relative incidence of NK cell functional deficiencies in CFS disease. This review indicates that low NK cell cytotoxicity (NKCC) has been consistently reported in CFS patients compared to normal controls. In the new laboratory studies, Ampligen(R) (rintatolimod), an experimental therapeutic, was found to increase in vitro NK activity utilizing cells from CFS patient donors. The authors of the new report are all affiliated with Hemispherx.
HEB: 0.22 (-0.01)
Hemispherx Biopharma FY14 results
Seeking Alpha - at Seeking Alpha - Fri Mar 20, 8:52AM CDT
HEB: 0.22 (-0.01)
Hemispherx Biopharma reports FY2014 results
Seeking Alpha - at Seeking Alpha - Fri Mar 20, 8:37AM CDT
HEB: 0.22 (-0.01)
Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2014
GlobeNewswire - Fri Mar 20, 8:28AM CDT
Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the year ended December 31, 2014. The net loss (including non-cash effects) was approximately $17,450,000 or $(0.09) per share as compared to a net loss of $16,225,000 or ($0.10) per share for the same twelve month period in 2013. Cash, cash equivalents and marketable securities were approximately $16,108,000 at December 31, 2014 as compared to $18,194,000 as of December 31, 2013.
HEB: 0.22 (-0.01)
Hemispherx Uses Ebola Tragedy to Raise Cash, Pay Executive Bonuses
at The Street - Tue Mar 10, 10:10AM CDT
Since the end of September, Hemispherx sold almost 25 million shares of company stock, equivalent to the amount of stock sold in the first nine months of 2014.
VRTX: 131.00 (-3.25), SGEN: 38.86 (-0.83), HEB: 0.22 (-0.01)
Hemispherx Enters a Collaboration with Emerge Health for the Commercialization of Ampligen for Chronic Fatigue Syndrome (CFS) in Australia and New Zealand
GlobeNewswire - Mon Mar 09, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
, reported today that it has executed an agreement with Emerge Health Pty Ltd. ("Emerge" to seek approval of Ampligen, an experimental immunotherapeutic, for Chronic Fatigue Syndrome in Australia and New Zealand and to commence distribution of Ampligen in both countries on a named-patient basis, where deemed appropriate. HEB: 0.22 (-0.01)
Regulators Want Drug Companies to Be Honest About FDA
at The Street - Wed Mar 04, 12:08PM CST
The Securities and Exchange Commission's top cop wants drug companies to be more transparent with investors about their dealings with the U.S. Food and Drug Administration.
HEB: 0.22 (-0.01), AVEO: 1.35 (-0.16), AMPE: 8.52 (+0.08), SNY: 50.64 (+1.17)
Hemispherx Biopharma Announces the Completion of the Newly Upgraded Alferon(R) Facility: Commercial Production of Alferon(R) is in the Final Stage Integrating Continuous Flow Manufacturing Technology
GlobeNewswire - Mon Mar 02, 7:30AM CST
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
announced today that its manufacturing site located in New Brunswick, New Jersey, presently configured at over 43,000 square feet, has completed its $8 million of upgrades. These upgrades will provide for a higher capacity, more cost effective manufacturing process for the production of Alferon N Injection(R), the only FDA-approved natural alpha interferon. The added efficiency of the process has been accomplished by integrating continuous flow manufacturing technology throughout the process. This has led to improved cost efficiency, enhanced yields, real-time process monitoring, flexibility to tailor batch size for lean manufacturing, and improved operational safety as seen in other cutting edge pharmaceutical companies. HEB: 0.22 (-0.01)
Biotech Weekly: 5 Factors Contributing To The Crazy Week That Was In Small Cap Biotech
Daniel Ward - at Seeking Alpha - Mon Feb 23, 7:40AM CST
HEB: 0.22 (-0.01), XBI: 233.86 (-4.12), IBIO: 0.79 (+0.02), IBB: 366.52 (+1.27), SPPI: 6.17 (-0.24), CLTX: 0.85 (+0.02)
WHO approves rapid test for Ebola
Seeking Alpha - at Seeking Alpha - Fri Feb 20, 6:15AM CST
BCRX: 9.49 (-0.74), TKMR: 19.48 (-1.01), GSK: 48.81 (+0.60), INO: 9.09 (-0.36), JNJ: 102.40 (+0.71), CMRX: 40.61 (-1.50), NVAX: 9.58 (-0.13), HEB: 0.22 (-0.01), MRK: 58.58 (+0.37), SRPT: 13.16 (-0.76), NLNK: 54.57 (-1.36), ABIO: 0.82 (-0.01), IBIO: 0.79 (+0.02)
What's New in the Biotechnology Sector: Special Research on Vical,Asterias, Bacterin, Hemispherx BioPharma, and IGI Laboratories
PR Newswire - Thu Feb 19, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
VICL: 0.97 (+0.01), BONE: 4.20 (-0.04), HEB: 0.22 (-0.01), AST: 7.88 (-0.40), IG: 9.32 (+0.65)
Hemispherx Biopharma and USAMRIID to Present New Discoveries Concerning the Efficacy of Ampligen(R) Against the Ebola Virus at Upcoming International Symposium on Filoviruses
GlobeNewswire - Thu Feb 12, 7:30AM CST
Ampligen(R) May Be an Important Candidate for EBOV Testing in West Africa
HEB: 0.22 (-0.01)
U.S. to pull troops from Ebola zone
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:38AM CST
INO: 9.09 (-0.36), JNJ: 102.40 (+0.71), BCRX: 9.49 (-0.74), HEB: 0.22 (-0.01), NLNK: 54.57 (-1.36), TKMR: 19.48 (-1.01), NNVC: 2.58 (-0.14), GSK: 48.81 (+0.60)
Hemispherx Biopharma Posts USAMRIID Ebola Study Concluding Ampligen(R) Produced 100% Survival Rate in Rodents With 100% Mortality in Placebo
GlobeNewswire - Mon Feb 09, 7:30AM CST
Based upon numerous Hemispherx stockholder requests, Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
has posted the report and findings of the recent efficacy study of Ampligen(R) in a mouse model of Ebola virus infection performed by scientists at the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID). The posted USAMRIID report conclusively refutes false and defamatory blog and online statements by TheStreet.com's blogger Adam Feuerstein and invalidates Feuerstein's negative social media postings about the company's press release that was issued on February 2, 2015. HEB: 0.22 (-0.01)
Biotech Stock Mailbag: Hep C stocks, Bluebird, Advaxis, Hemispherx
at The Street - Fri Feb 06, 5:05AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
BLUE: 124.76 (-1.64), ADXS: 12.54 (+0.14), GILD: 102.29 (+0.85), HEB: 0.22 (-0.01), ACHN: 11.06 (-0.36), MRK: 58.58 (+0.37), ABBV: 60.40 (-0.79)
U.S. Army Medical Researchers to Hemispherx: We're Really Not That Into You
at The Street - Wed Feb 04, 11:59AM CST
A spokeswoman for the U.S. Army Medical Research Institute says its testing of Alferon and Ampligen drugs for ebola is complete and the relationship has ended.
HEB: 0.22 (-0.01)
Hemispherx: U.S. Army Scientists (USAMRIID) Find Ampligen(R) Produces 100% Survival Rate in Ebola Virus Rodent Study
GlobeNewswire - Mon Feb 02, 9:05AM CST
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
, announced today the results of a new efficacy study of Ampligen(R) in a mouse model of Ebola virus (EBOV) infection performed by scientists at the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID). HEB: 0.22 (-0.01)
USAMRIID Reports Genetic Changes in Ebola Virus May Impede Potential Treatments
GlobeNewswire - Mon Jan 26, 7:30AM CST
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
, announced today that in a new publication in the journal mBio, scientists at the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID), Harvard University, and Massachusetts Institute of Technology (MIT) studied genetic changes in the Ebola virus (EBOV) circulating in West Africa and concluded that genomic drift of the EBOV over time may be sufficient to block the action of otherwise potential therapies that target EBOV genetic sequences. The types of potential drugs at risk include monoclonal antibodies and small-interfering RNA (siRNA) which are scheduled to be evaluated during the current outbreak (see below). The USAMRIID press release states that "genetic drift must be considered when developing potential therapeutics, in order to ensure that changes in the Ebola virus over time do not render those treatments ineffective......the USAMRIID team compared the current strain, called EBOV/Mak, with the two previous strains that caused outbreaks in 1976 and 1995 in Zaire (now the Democratic Republic of the Congo). In each comparison, they found more than 600 genetic mutations. Next, the group focused on only the mutations that occurred in the genetic sequences targeted by the experimental therapeutics. Of these, they found 10 new mutations that might interfere with the mechanisms of the sequence-based drugs currently being tested. Three of these mutations appeared during the current West African outbreak." (http://www.usamriid.army.mil/newsroom.htm). HEB: 0.22 (-0.01)
NanoViricides up on report of Ebola drug progress
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 11:12AM CST
INO: 9.09 (-0.36), BCRX: 9.49 (-0.74), CMRX: 40.61 (-1.50), HEB: 0.22 (-0.01), SRPT: 13.16 (-0.76), ABIO: 0.82 (-0.01), TKMR: 19.48 (-1.01), NNVC: 2.58 (-0.14)
Hemispherx Biopharma Awarded $770,852 by Federal Judge
GlobeNewswire - Thu Jan 15, 7:59AM CST
Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx"
announced that after prevailing in a federal lawsuit brought against the Company by Cato Capital, the United States District Court for the District of Delaware has ordered Cato to pay Hemispherx attorney's fees and costs in the amount of $770,852.76. Previously, in September 2014, the Court dismissed all claims brought by Cato against Hemispherx, including counts of breach of contract and fraudulent inducement--completely vindicating the Company of any wrongdoing. HEB: 0.22 (-0.01)
Low Natural Killer (NK) Activity Observed Across the Chronic Fatigue Syndrome (CFS) Disease Spectrum
GlobeNewswire - Mon Jan 12, 8:16AM CST
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
, reported today that it has conducted new in vitro studies of natural killer (NK) cells obtained from CFS patients in conjunction with a comprehensive review of the medical literature to determine the relative incidence of NK cell functional deficiencies in CFS disease. This review indicates that low NK cell cytotoxicity (NKCC) has been consistently reported in CFS patients compared to normal controls. In the new laboratory studies, Ampligen(R) (rintatolimod), an experimental therapeutic, was found to increase in vitro NK activity utilizing cells from CFS patient donors. The authors of the new report are all affiliated with Hemispherx. HEB: 0.22 (-0.01)
